Home > Newsletters > FDAnews Drug Daily Bulletin > Expert: Leave FDA Free to Create Biogenerics Approval Path
FDAnews Drug Daily Bulletin
Oct. 3, 2008 | Vol. 5 No. 194
Expert: Leave FDA Free to Create Biogenerics Approval Path
As Congress drafts legislation to create a pathway for biogeneric approval, lawmakers should limit mandates that could hinder the FDA’s ability to make decisions about clinical trials and bioequivalence testing, Gregory Conko, a senior fellow at the Competitive Enterprise Institute, said at the Generic Pharmaceutical Association’s Annual Policy Conference. For instance, Congress should not mandate clinical trials but allow the FDA to decide on a case-by-case basis whether such testing is needed, he said. Giving the FDA discretion in this area will spur innovation and development of assays to prove bioequivalence.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.